Molecular medicine company modernizes validation to reduce risk and cost

A clinical-stage precision medicine company faced "validation debt" from managing software validation through manual, paper-based processes that grew more burdensome as release frequency and regulatory demands increased. It adopted Sware's Res_Q platform to shift from computer software validation (CSV) to computer software assurance (CSA) using automated, paperless workflows. The company can now manage over 30 internal and external releases per quarter with fewer staff, reducing validation time from days to hours; its IT leader noted, "Validation workstreams that weren't in Res_Q took days...take hours" after adopting the system. Outcomes included reallocating personnel away from validation tasks, reduced deployment time, and alignment with FDA recommendations on GxP digitization.

Sware is a GxP validation platform whose entire commercial focus is life sciences — used specifically to validate AI/ML systems' explainable, traceable decisions for regulatory scrutiny.

This sits in the Scale & Govern stage of the AI use-case lifecycle: Named examples from the tools pharma teams use to monitor, govern and keep validating an AI system once it is already live in production.